Get the Stockscreener App
8.08
0.37%
-0.03
Tango Therapeutics Inc stock is traded at $8.08, with a volume of 1.47M.
It is down -0.37% in the last 24 hours and up +4.12% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$8.11
Open:
$7.96
24h Volume:
1.47M
Relative Volume:
0.55
Market Cap:
$897.87M
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-6.0752
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
+3.99%
1M Performance:
+4.12%
6M Performance:
+435.10%
1Y Performance:
+56.89%
1-Day Range:
$7.74
$8.14
1-Week Range:
$7.57
$8.35
52-Week Range:
$1.03
$9.70
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
8.07 | 1.07B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
Can Tango Therapeutics Inc. stock outperform in 2025 bull market2025 Year in Review & Growth Oriented Trade Recommendations - newser.com
Does Tango Therapeutics Inc. fit your quant trading modelAnalyst Upgrade & High Accuracy Swing Trade Signals - newser.com
Will Tango Therapeutics Inc. stock attract ESG investorsJuly 2025 Setups & Weekly Watchlist for Hot Stocks - newser.com
Tango Therapeutics Inc (TNGX) Q3 2025 Earnings Report Preview: W - GuruFocus
Tango Therapeutics Inc (TNGX) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Why Tango Therapeutics Inc. is moving todayQuarterly Growth Report & Accurate Intraday Trading Signals - newser.com
Long term hold vs stop loss in Tango Therapeutics Inc.Swing Trade & Accurate Intraday Trading Signals - newser.com
How Tango Therapeutics Inc. stock performs in rising dollar environmentTrade Volume Report & Short-Term High Return Ideas - newser.com
Short interest data insights for Tango Therapeutics Inc.Treasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Ranking Tango Therapeutics Inc. among high performing stocks via toolsWeekly Profit Analysis & Long-Term Safe Investment Plans - newser.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Tango Therapeutics Inc. stock trend outlook and recovery pathIndex Update & Low Volatility Stock Recommendations - newser.com
Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet - sharewise.com
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - AOL.com
Why Tango Therapeutics Inc. stock is trending among retail tradersJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
What is HC Wainwright's Estimate for TNGX FY2026 Earnings? - MarketBeat
Is Tango Therapeutics Inc. stock entering bullish territoryMarket Movers & Consistent Growth Equity Picks - newser.com
How to build a dashboard for Tango Therapeutics Inc. stock2025 Trade Ideas & Expert Verified Stock Movement Alerts - newser.com
Will Tango Therapeutics Inc. stock maintain dividend yield2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Multi asset correlation models including Tango Therapeutics Inc.Market Growth Review & High Conviction Investment Ideas - newser.com
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? - Mitrade
Tango Therapeutics price target raised to $12 from $10 at Guggenheim - MSN
Tango Therapeutics’ Promising Update on TNG260 Clinical Study - MSN
TNGX FY2025 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
Revolution Medicines and Tango Therapeutics Advance in Targeted Cancer Therapy Study - MSN
Tango Therapeutics (TNGX) Expected to Announce Earnings on Wednesday - MarketBeat
Tango Therapeutics Inc. (TNGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Tango Therapeutics Advances Innovative Cancer Treatment with S095035 Clinical Trial - TipRanks
Why Tango Therapeutics (TNGX) Surged After Positive Vopimetostat Trial Results and Major Capital Raise - Yahoo Finance
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - The Manila Times
Tango (NASDAQ: TNGX) will report third quarter results Nov 4; no conference call - Stock Titan
Tango Therapeutics (TNGX) Price Target Increased by 11.49% to 12.37 - Nasdaq
Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells 477,401 Shares of Stock - MarketBeat
Tango Therapeutics Stock Fell 15% in a Week, What Now? - Trefis
Will Tango Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Spike Watch & Free Verified High Yield Trade Plans - fcp.pa.gov.br
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):